{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:12:51Z","timestamp":1763727171927,"version":"3.37.3"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T00:00:00Z","timestamp":1493251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"MINECO","award":["SAF2015-68580-C2-1-R"],"award-info":[{"award-number":["SAF2015-68580-C2-1-R"]}]},{"name":"CIBERNED","award":["CB06\/05\/0089"],"award-info":[{"award-number":["CB06\/05\/0089"]}]},{"DOI":"10.13039\/100008980","name":"Medical College of Wisconsin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008980","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/NEU-NMC\/3648\/2014"],"award-info":[{"award-number":["PTDC\/NEU-NMC\/3648\/2014"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0176521","type":"journal-article","created":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T19:49:56Z","timestamp":1493322596000},"page":"e0176521","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Altered striatal endocannabinoid signaling in a transgenic mouse model of spinocerebellar ataxia type-3"],"prefix":"10.1371","volume":"12","author":[{"given":"Carmen","family":"Rodr\u00edguez-Cueto","sequence":"first","affiliation":[]},{"given":"Mariluz","family":"Hern\u00e1ndez-G\u00e1lvez","sequence":"additional","affiliation":[]},{"given":"Cecilia J.","family":"Hillard","sequence":"additional","affiliation":[]},{"given":"Patricia","family":"Maciel","sequence":"additional","affiliation":[]},{"given":"Sara","family":"Valdeolivas","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 A.","family":"Ramos","sequence":"additional","affiliation":[]},{"given":"Mar\u00eda","family":"G\u00f3mez-Ruiz","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4490-0604","authenticated-orcid":true,"given":"Javier","family":"Fern\u00e1ndez-Ruiz","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2017,4,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1517\/14728221003709792","article-title":"The endocannabinoid system as a target for the treatment of neuronal damage","volume":"14","author":"J Fern\u00e1ndez-Ruiz","year":"2010","journal-title":"Expert Opin Ther Targets"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/978-3-319-20825-1_8","article-title":"Endocannabinoids and neurodegenerative disorders: Parkinson&apos;s disease, Huntington&apos;s chorea, Alzheimer&apos;s disease, and others","volume":"231","author":"J Fern\u00e1ndez-Ruiz","year":"2015","journal-title":"Handb Exp Pharmacol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s13311-015-0381-7","article-title":"Cannabinoids in neurodegenerative disorders and stroke\/brain trauma: from preclinical models to clinical applications","volume":"12","author":"J Fern\u00e1ndez-Ruiz","year":"2015","journal-title":"Neurotherapeutics"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.tips.2006.11.001","article-title":"Cannabinoid CB2 receptor: a new target for controlling neural cell survival?","volume":"28","author":"J Fern\u00e1ndez-Ruiz","year":"2007","journal-title":"Trends Pharmacol Sci"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.phrs.2016.07.021","article-title":"Type-2 cannabinoid receptors in neurodegeneration","volume":"111","author":"T Bisogno","year":"2016","journal-title":"Pharmacol Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1517\/14728222.2015.1043268","article-title":"The effect of endocannabinoid system in ischemia-reperfusion injury: a friend or a foe?","volume":"19","author":"D Moris","year":"2015","journal-title":"Expert Opin Ther Targets"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1111\/j.1476-5381.2011.01343.x","article-title":"Endocannabinoids and traumatic brain injury","volume":"163","author":"E Shohami","year":"2011","journal-title":"Br J Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.pnpbp.2015.03.008","article-title":"Cannabinoids to treat spinal cord injury","volume":"64","author":"A Arevalo-Martin","year":"2016","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1042\/BST20130140","article-title":"Endocannabinoid signalling in Alzheimer&apos;s disease","volume":"41","author":"N Maroof","year":"2013","journal-title":"Biochem Soc Trans"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.pnpbp.2015.03.017","article-title":"Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson&apos;s disease","volume":"64","author":"Y G\u00f3mez-G\u00e1lvez","year":"2016","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/glia.20838","article-title":"Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington&apos;s disease","volume":"57","author":"O Sagredo","year":"2009","journal-title":"Glia"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1093\/brain\/awp239","article-title":"Microglial CB2 cannabinoid receptors are neuroprotective in Huntington&apos;s disease excitotoxicity","volume":"132","author":"J Palazuelos","year":"2009","journal-title":"Brain"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1471-2377-6-12","article-title":"COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells\/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord","volume":"6","author":"Y Yiangou","year":"2006","journal-title":"BMC Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s11481-015-9602-4","article-title":"Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders","volume":"10","author":"F Espejo-Porras","year":"2015","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1111\/bph.12283","article-title":"Changes in CB<sub>1<\/sub> and CB<sub>2<\/sub> receptors in the <italic>post-mortem<\/italic> cerebellum of humans affected by spinocerebellar ataxias","volume":"171","author":"C Rodr\u00edguez-Cueto","year":"2014","journal-title":"Brit J Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000358127","article-title":"Endocannabinoid-hydrolysing enzymes in the <italic>post-mortem<\/italic> cerebellum of humans affected by hereditary autosomal dominant ataxias","volume":"81","author":"C Rodr\u00edguez-Cueto","year":"2014","journal-title":"Pathobiology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.neuroscience.2016.09.046","article-title":"Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3","volume":"339","author":"C Rodr\u00edguez-Cueto","year":"2016","journal-title":"Neuroscience"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S1474-4422(10)70183-6","article-title":"Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond","volume":"9","author":"A Durr","year":"2010","journal-title":"Lancet Neurol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/WCO.0b013e32834875ba","article-title":"Update on degenerative ataxias","volume":"24","author":"T Klockgether","year":"2011","journal-title":"Curr Opin Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-012-1000-x","article-title":"Brain pathology of spinocerebellar ataxias","volume":"124","author":"K Seidel","year":"2012","journal-title":"Acta Neuropathol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.pneurobio.2013.01.001","article-title":"Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7","volume":"104","author":"U R\u00fcb","year":"2013","journal-title":"Prog Neurobiol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/B978-0-444-51892-7.00027-9","article-title":"Machado-Joseph disease\/spinocerebellar ataxia type 3","volume":"103","author":"H Paulson","year":"2012","journal-title":"Handb Clin Neurol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/B978-0-444-51892-7.00005-X","article-title":"Neuropathology of degenerative ataxias","volume":"103","author":"JD Fratkin","year":"2012","journal-title":"Handb Clin Neurol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/978-1-4614-0653-2_14","article-title":"Machado-Joseph disease and other rare spinocerebellar ataxias","volume":"724","author":"A Matilla-Due\u00f1as","year":"2012","journal-title":"Adv Exp Med Biol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/nan.12253","article-title":"Polyglutamine aggregation in Huntington&apos;s disease and spinocerebellar ataxia type 3: similar mechanisms in aggregate formation","volume":"42","author":"K Seidel","year":"2016","journal-title":"Neuropathol Appl Neurobiol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s12311-008-0013-4","article-title":"SCA3: neurological features, pathogenesis and animal models","volume":"7","author":"O Riess","year":"2008","journal-title":"Cerebellum"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S1474-4422(13)70104-2","article-title":"Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data","volume":"12","author":"H Jacobi","year":"2013","journal-title":"Lancet Neurol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s13311-013-0255-9","article-title":"Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado-Joseph disease","volume":"11","author":"A Silva-Fernandes","year":"2014","journal-title":"Neurotherapeutics"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/archneur.55.1.33","article-title":"Characteristic magnetic resonance imaging findings in Machado-Joseph disease","volume":"55","author":"Y Murata","year":"1998","journal-title":"Arch Neurol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1080\/14734220510007950","article-title":"The pathogenesis of spinocerebellar ataxia","volume":"4","author":"AH Koeppen","year":"2005","journal-title":"Cerebellum"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1007\/s00415-012-6531-5","article-title":"Tremor-spectrum in spinocerebellar ataxia type 3","volume":"259","author":"C Bonnet","year":"2012","journal-title":"J Neurol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/sj.bjp.0705334","article-title":"The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase","volume":"139","author":"S Patel","year":"2003","journal-title":"Br J Pharmacol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1093\/hmg\/ddn106","article-title":"Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease","volume":"17","author":"S Alves","year":"2008","journal-title":"Hum Mol Genet"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1002\/mds.25527","article-title":"The anatomical basis of dystonia: current view using neuroimaging","volume":"28","author":"S Leh\u00e9ricy","year":"2013","journal-title":"Mov Disord"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.pneurobio.2015.02.002","article-title":"Striatal cholinergic dysfunction as a unifying theme in the pathophysiology of dystonia","volume":"127\u2013128","author":"KL Eskow Jaunarajs","year":"2015","journal-title":"Prog Neurobiol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/brain\/awq278","article-title":"Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington&apos;s disease","volume":"134","author":"C Bl\u00e1zquez","year":"2011","journal-title":"Brain"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1111\/j.1476-5381.2011.01365.x","article-title":"Prospects for cannabinoid therapies in basal ganglia disorders","volume":"163","author":"J Fern\u00e1ndez-Ruiz","year":"2001","journal-title":"Br J Pharmacol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/syn.20047","article-title":"Immunolocalization of CB1 receptor in rat striatal neurons: a confocal microscopy study","volume":"53","author":"FR Fusco","year":"2004","journal-title":"Synapse"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.nbd.2008.03.011","article-title":"Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation","volume":"31","author":"AH Chou","year":"2008","journal-title":"Neurobiol Dis"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.clinph.2013.01.003","article-title":"Dystonia and the cerebellum: a new field of interest in movement disorders?","volume":"124","author":"P Filip","year":"2013","journal-title":"Clin Neurophysiol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/mds.20214","article-title":"\u0394<sup>9<\/sup>-tetrahydrocannabinol improves motor control in a patient with musician&apos;s dystonia","volume":"19","author":"HC Jabusch","year":"2004","journal-title":"Mov Disord"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0014-2999(02)02477-9","article-title":"Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia","volume":"454","author":"A Richter","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrn3876","article-title":"Endocannabinoid signalling and the deteriorating brain","volume":"16","author":"V Di Marzo","year":"2015","journal-title":"Nat Rev Neurosci"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0176521","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T21:04:45Z","timestamp":1589749485000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0176521"}},"subtitle":[],"editor":[{"given":"David R","family":"Borchelt","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2017,4,27]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,4,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0176521","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2017,4,27]]}}}